A detailed history of Quest Partners LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 7,458 shares of NRIX stock, worth $147,892. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,458
Previous 6,146 21.35%
Holding current value
$147,892
Previous $128 Million 30.65%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$18.93 - $25.69 $24,836 - $33,705
1,312 Added 21.35%
7,458 $168 Million
Q2 2024

Aug 06, 2024

SELL
$12.02 - $21.3 $36,396 - $64,496
-3,028 Reduced 33.01%
6,146 $128 Million
Q1 2024

May 09, 2024

BUY
$7.77 - $15.66 $26,798 - $54,011
3,449 Added 60.24%
9,174 $135 Million
Q4 2023

Feb 09, 2024

BUY
$4.25 - $10.71 $24,331 - $61,314
5,725 New
5,725 $59.1 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.